Evidence map›Paper›PMID 40418347›Full record

ReviewZeitschrift fur Rheumatologie2025

[Innovative treatments in rheumatology].

Abhinav Singla, Christof Iking-Konert, Carolin Kellersmann, Dimitrios Mougiakakos, Eugen Feist

Erratum issuedAbstract readReviewEnglish Abstract
PubMed Publisher
In one paragraph

Review in Zeitschrift fur Rheumatologie, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

5 authors.

Abhinav SinglaHelios Fachklinik Vogelsang-Gommern, Sophie-von-Boetticher-Str. 1, 39245, Vogelsang-Gommern, Deutschland. Abhinav.Singla@helios-gesundheit.de.
Christof Iking-KonertStadtspital Zürich, Zürich, Schweiz.
Carolin KellersmannHeinrich-Heine-Universität, Düsseldorf, Deutschland.
Dimitrios MougiakakosUniversitätsklinik für Hämatologie, Onkologie und Zelltherapie, Medizinische Fakultät, Otto-von-Guericke-Universität Magdeburg, Magdeburg, Deutschland.
Eugen FeistHelios Fachklinik Vogelsang-Gommern, Sophie-von-Boetticher-Str. 1, 39245, Vogelsang-Gommern, Deutschland.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Systemic rheumatic diseases represent a heterogeneous group of conditions associated with significant morbidity and substantial healthcare burden. Their clinical course varies widely and is influenced by genetic, immunologic, and environmental factors. Despite advances in pharmacotherapy, conventional immunomodulatory and immunosuppressive treatments often remain insufficiently effective or lose efficacy over time. The identification of novel molecular targets is crucial to enable more precise and effective therapies. Advances in understanding pathogenic signaling pathways have led to the development of innovative therapeutic agents. This review highlights current and emerging molecular and cell-based therapies that are either recently approved or in clinical development, with a special focus on their mechanisms of action and potential to support personalized treatment approaches in rheumatic diseases.

Indexed as

Antirheumatic AgentsMolecular Targeted TherapyRheumatic DiseasesRheumatologyTherapies, InvestigationalEvidence-Based MedicineHumansImmunosuppressive AgentsPrecision MedicineAntirheumatic AgentsImmunosuppressive AgentsCell-directed treatmentDrug therapyMolecular targetsPathogenic signaling pathwaysTherapeutic target molecules

Identifiers

PMID40418347

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.